Head-to-head evidence
Dorzagliatin vs SY-004
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Glucokinase · full Type 2 Diabetes pipeline
Dorzagliatin · Huatangning
Developed by Hua Medicine
NCT04531631 · Phase 2 · completed
The study used randomized, triple-blind, placebo-controlled crossover treatment, but enrolled only 18 participants and measured a mechanistic insulin-response biomarker rather than a clinical diabetes outcome. Because the registry provides no primary-endpoint results, it is not possible to determine whether the comparison met its prespecified endpoint.
Next expected readout: March 2029 · NCT07786571 (registry estimate)
SY-004
Developed by Suzhou Yabao Pharmaceutical
NCT04217291 · Phase 2 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 200 participants, but its primary endpoint was the surrogate measure of change in HbA1c rather than a hard clinical outcome. Because the registry does not report whether the primary comparison was favorable or statistically significant, the evidence is limited to a moderate grade.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dorzagliatin's landscape · SY-004's landscape